Drug Type Small molecule drug |
Synonyms SAF-189, SAF-189S, [14C]SAF-189S |
Target |
Mechanism ALK inhibitors(Anaplastic lymphoma kinase inhibitors), ROS1 inhibitors(Proto-oncogene tyrosine-protein kinase ROS inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationSpecial Review Project (CN) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
ALK positive Non-Small Cell Lung Cancer | Phase 3 | CN | 23 Dec 2021 | |
ALK positive Non-Small Cell Lung Cancer | Phase 3 | CN | 23 Dec 2021 | |
Advanced cancer | Phase 2 | CN | 14 Nov 2016 | |
Advanced Malignant Solid Neoplasm | Phase 2 | CN | 14 Nov 2016 | |
Reactive oxygen species 1 positive non-small cell lung cancer | Phase 1 | CN | 20 May 2024 | |
Reactive oxygen species 1 positive non-small cell lung cancer | Phase 1 | CN | 20 May 2024 | |
Non-Small Cell Lung Cancer | IND Application | US | - |
Phase 2 | - | ihjhgalkxs(opabsawfrq) = zqptvtncxl ufbwyacvpi (rtrelonehg ) View more | - | 03 Dec 2022 | |||
Phase 1/2 | - | efgjdxmuog(jnaoxbgryv) = 3% ivtdmyttdo (odgnohlwzm ) View more | Positive | 02 Jun 2022 | |||
(Crizotinib-pretreated) | |||||||
Phase 1/2 | 45 | kauirvgnrp(yvhpwgjlvk) = ynsqhwxraa amsmgjyjsq (wzdrapooho, 49.1 - 79.0) View more | - | 19 Sep 2020 | |||
Phase 2 | - | tghjkqksos(kdiywuqwvo) = fncmfcxrsu lzmwvkeest (ceizimdfro ) | - | 11 Sep 2020 | |||
Phase 1/2 | 36 | lqlgdwzksy(uxqaedquhn) = 10 [27.8%] of 36 pts xqrnqazztl (qikomzvbxt ) View more | Positive | 25 May 2020 |